Shareholders Equity and Capital Stock (Details 4) - USD ($) |
12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Number of RSUs | 641,910 | 305,530 | 1,011,660 | 1,404,962 |
Weighted-Average Remaining contractual life (years) | 1 year 6 months | |||
Aggregate Intrinsic Value | $ 988,541 | |||
January 04, 2025 [Member] | ||||
Number of RSUs | 332,850 | |||
Weighted-Average Remaining contractual life (years) | 1 year | |||
Aggregate Intrinsic Value | $ 512,589 | |||
Redemption date | Jan. 04, 2025 | |||
December 07, 2025 [Member] | ||||
Number of RSUs | 309,060 | |||
Weighted-Average Remaining contractual life (years) | 1 year 10 months 24 days | |||
Aggregate Intrinsic Value | $ 475,952 | |||
Redemption date | Dec. 07, 2025 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|